Zacks: Analysts Expect GALAPAGOS NV/S (GLPG) Will Announce Quarterly Sales of $82.15 Million

Equities analysts predict that GALAPAGOS NV/S (NASDAQ:GLPG) will post sales of $82.15 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for GALAPAGOS NV/S’s earnings, with the highest sales estimate coming in at $109.85 million and the lowest estimate coming in at $54.45 million. GALAPAGOS NV/S reported sales of $39.16 million during the same quarter last year, which indicates a positive year-over-year growth rate of 109.8%. The business is scheduled to issue its next quarterly earnings results on Tuesday, October 23rd.

On average, analysts expect that GALAPAGOS NV/S will report full year sales of $266.61 million for the current financial year, with estimates ranging from $234.28 million to $283.22 million. For the next fiscal year, analysts anticipate that the company will report sales of $217.37 million per share, with estimates ranging from $146.09 million to $264.60 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow GALAPAGOS NV/S.

Several research analysts recently commented on GLPG shares. BidaskClub raised GALAPAGOS NV/S from a “hold” rating to a “buy” rating in a research note on Thursday, July 19th. Morgan Stanley upped their price objective on GALAPAGOS NV/S from $125.00 to $126.00 and gave the stock an “overweight” rating in a research report on Friday, July 13th. Zacks Investment Research raised GALAPAGOS NV/S from a “hold” rating to a “buy” rating and set a $114.00 price objective for the company in a research report on Tuesday, July 17th. ValuEngine raised GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 28th. Finally, Cowen reaffirmed a “buy” rating on shares of GALAPAGOS NV/S in a research report on Thursday, May 31st. Four investment analysts have rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the stock. GALAPAGOS NV/S presently has an average rating of “Buy” and an average price target of $109.00.

GALAPAGOS NV/S traded down $4.79, hitting $108.26, on Tuesday, according to MarketBeat.com. 45,920 shares of the company were exchanged, compared to its average volume of 80,168. GALAPAGOS NV/S has a twelve month low of $81.44 and a twelve month high of $121.09.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. grew its holdings in GALAPAGOS NV/S by 32.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 2,315 shares of the biotechnology company’s stock valued at $217,000 after buying an additional 573 shares during the last quarter. Provident Investment Management Inc. acquired a new stake in GALAPAGOS NV/S during the 2nd quarter valued at $249,000. Citadel Advisors LLC grew its holdings in GALAPAGOS NV/S by 24.3% during the 1st quarter. Citadel Advisors LLC now owns 3,566 shares of the biotechnology company’s stock valued at $356,000 after buying an additional 696 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in GALAPAGOS NV/S during the 1st quarter valued at $636,000. Finally, Stanley Laman Group Ltd. acquired a new stake in GALAPAGOS NV/S during the 2nd quarter valued at $720,000. Institutional investors and hedge funds own 17.34% of the company’s stock.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

See Also: Find a Trading Strategy That Works

Get a free copy of the Zacks research report on GALAPAGOS NV/S (GLPG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply